Mammoth Biosciences Named to the 2020 CB Insights 150 Most Innovative Digital Health Startups List

CB Insights today named Mammoth Biosciences to its second annual Digital Health 150 list, which showcases the 150 most promising private digital health companies in the world. The honor comes on the heels of a landmark year for Mammoth Biosciences, which has seen great success across its CRISPR-enabled platforms for both disease detection and therapeutic applications.

The 2020 Digital Health 150 cohort highlights startups that are reimagining the lines of the traditional healthcare experience across 12 categories, from Virtual Care Delivery and Clinical Trials, to Drug Discovery and Specialty Care. Countries represented this year include Canada, China, Israel, France, the United Kingdom, and the United States, among others. 

Mammoth has announced several major initiatives and accomplishments in recent months related to their CRISPR-based disease detection platform, DETECTR™, and broader CRISPR toolkit. Some of the most noteworthy include: 

• Secured exclusive licensing to the newly discovered Casɸ family of CRISPR proteins from UC Berkeley 
• Awarded a grant from the NIH Rapid Acceleration of Diagnostics (RADx) program to address the testing shortage with its high-throughput COVID-19 testing
• Announced a collaboration with GSK Consumer Healthcare for rapid, highly-accurate at-home e CRISPR-based tests for COVID-19
• Published peer-reviewed validation of its DETECTR platform to detect SARS-CoV-2 from respiratory swab RNA extracts in under 45 minutes

“Since founding Mammoth in 2017, we have sought to bring CRISPR out of the lab to reimagine individuals’ relationships with their health. We’re honored to be included in this year’s CB Insights Most Innovative Digital Health Startups list for our work with COVID and CRISPR-based disease detection,” said Mammoth CEO and co-founder Trevor Martin. “We’re thrilled to continue the momentum built over this past year to strengthen our IP, grow our team, advance our R&D, and form more strong partnerships.”

Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from hundreds of applications based on several factors including patent activity, investor quality, news sentiment analysis, proprietary Mosaic scores, market potential, partnerships, competitive landscape, team strength, and tech novelty. The Mosaic Score, based on CB Insights’ algorithm, measures the overall health and growth potential of private companies to help predict a company’s momentum. 

“This year’s Digital Health 150 is our most global ever, covering the best private healthcare companies from 17 countries. Beyond geographic diversity, these companies are innovating across the entire healthcare value chain, spanning technologies that benefit pharma & biotech companies, to payers, hospitals, insurers, and more,” said CB Insights CEO Anand Sanwal. “Last year’s Digital Health 150 winners saw numerous exits and went on to raise nearly $5 billion in investor financing after being recognized. We look forward to seeing the success of this year’s class of the best in digital health"  

Mammoth Biosciences is currently evaluating partnerships with companies adding complementary skills to leverage their CRISPR toolbox for disease detection or therapeutic applications. For more information, visit www.mammoth.bio.

Contact Information

Riley Munks

Media Contact

VSC for Mammoth Biosciences

mammoth@vsc.co